Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
You may also be interested in...
Sponsor would need “no pain” result at two hours, but could use patient-identified symptom as co-primary endpoint.
Sponsor would need ‘no pain’ result at two hours, but could use patient-identified symptom as co-primary endpoint.
The Irvine, Calif.-based company reported full-year results on Feb. 5 that highlighted the growth of its Botox business to several new indications.